CervoMed (CRVO) vs Werewolf Therapeutics (HOWL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Werewolf Therapeutics (HOWL) has outperformed CervoMed (CRVO) over the past year, losing 45.0% versus a loss of 62.3%. Over five years, CRVO leads with a -91.1% price change compared with -94.3% for HOWL. CervoMed is the larger company by market cap ($48.7 million vs $47.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVO | HOWL |
|---|---|---|
| Share price | $3.22 | $0.9796 |
| Market cap | $48.68M | $47.61M |
| 1-day change | -1.83% | +7.65% |
| YTD return | -59.24% | +54.51% |
| 1-year return | -62.30% | -44.97% |
| 5-year return | -91.06% | -94.26% |
| EPS (TTM) | $-3.13 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.00 | $1.85 |
| 52-week low | $2.13 | $0.27 |
| Distance from 52-week high | -67.80% | -47.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +378.26% | +614.58% |
| Average volume | 339.08K | 6.80M |
| Shares outstanding | 15.12M | 48.60M |
| Employees | 15 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HOWL has outperformed CRVO by 17.3 percentage points over the past year.
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
CRVO vs HOWL FAQ
Which is bigger, CervoMed or Werewolf Therapeutics?
CervoMed (CRVO) is larger, with a market capitalization of $48.68M compared with $47.61M for Werewolf Therapeutics (HOWL).
Which stock has performed better over the past year, CRVO or HOWL?
HOWL returned -44.97% over the past 12 months, compared with -62.30% for CRVO (price return, excluding dividends). Past performance does not predict future results.
Are CervoMed and Werewolf Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.